Homepage
Catalog of Screening Compounds
Screening Libraries
Focused and Target Libraries
Active Reference Sets
Diversity Libraries
Screening Compounds
Building blocks
Drug Discovery Services
Custom Chemistry
Medicinal chemistry
In silico Drug Design (CADD)
Discovery Biology
Animal Models
Toxicology and Safety
ADME, DMPK
Chemistry, Manufacturing and Controls
Company
News & Media
Contact us
For suppliers
Trends in discovery compounds
Homepage
>
Company
>
Media
>
Pharma News
>
2025
>
Mammoth Biosciences to Present Preclinical Data on MB-111
Mammoth Biosciences to Present Preclinical Data on MB-111
Read also
Ventus and Genentech
Ventus and Genentech partner for small-molecule medicine discovery
Aspire Pharma’s
Acquisition strengthens Aspire Pharma’s strategic portfolio
Alkermes to acquire Avadel for $2.1bn
Alkermes has agreed to acquire Avadel Pharmaceuticals for up to $20 per share in cash, valuing Avadel at $2.1bn.
NanoViricides
NanoViricides reports antiviral activity of NV-387 against measles in preclinical studies
